KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest Expenses (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Interest Expenses for 7 consecutive years, with $94.2 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 43.2% to $94.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $307.7 million through Dec 2025, up 36.43% year-over-year, with the annual reading at $307.7 million for FY2025, 36.43% up from the prior year.
  • Interest Expenses hit $94.2 million in Q4 2025 for Royalty Pharma, up from $79.6 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $94.2 million in Q4 2025 to a low of $37.4 million in Q1 2021.
  • Historically, Interest Expenses has averaged $53.7 million across 5 years, with a median of $47.0 million in 2021.
  • Biggest five-year swings in Interest Expenses: tumbled 30.18% in 2021 and later soared 47.54% in 2025.
  • Year by year, Interest Expenses stood at $47.0 million in 2021, then dropped by 0.04% to $47.0 million in 2022, then rose by 0.64% to $47.3 million in 2023, then surged by 39.16% to $65.8 million in 2024, then skyrocketed by 43.2% to $94.2 million in 2025.
  • Business Quant data shows Interest Expenses for RPRX at $94.2 million in Q4 2025, $79.6 million in Q3 2025, and $68.7 million in Q2 2025.